Category: Oncotarget

Oncotarget News

Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.

Leveraging Gold Nanostars for Precision Laser Interstitial Thermal Therapy

June 24, 2024

Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.”BUFFALO, NY- June 24, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 14, 2024, entitled, “Leveraging... read more

Oncotarget

Assessment of Serum Tumor Markers CEA, CA-125, and CA19-9 as Adjuncts in Non-small Cell Lung Cancer Management

June 19, 2024

these inexpensive, widely available tests with rapid turnaround times and relatively short half-lives (CEA, CA-125, and CA19-9) are perfectly situated to serve as adjunctive clinical tools in the management of... read more

Oncotarget

When Does a Melanoma Metastasize? Implications for Management

June 18, 2024

immunotherapy is more likely to be effective at eliminating metastatic disease if the tumor burden is low, making it more logical to treat patients with high-risk melanomas at the earliest... read more

Oncotarget

Oncotarget Sponsors 2024 Ride for Roswell

June 11, 2024

Impact Journals (Oncotarget's publisher) is thrilled to sponsor Team Open Access again in the annual cycling event to end cancer, The Ride for Roswell, on June 22, 2024.BUFFALO, NY-... read more

Figure 5: Effects of drugs on the levels of various proteins involved in DNA repair/DNA damage response.

Oncotarget

Synergistic Cytotoxicity of HDAC and PARP Inhibitors and Decitabine in Pancreatic Cancer Cells: Implications for Novel Therapy

June 5, 2024

The results provide novel preclinical data that demonstrate synergism between HDACi- and PARPi-mediated inhibition of DNA repair and decitabine in pancreatic cancer [...]”BUFFALO, NY- June 5, 2024 – A new research... read more

Oncotarget

BTK Inhibitor-related Cardiotoxicity: The Quest for Predictive Biomarkers and Improved Risk Stratification

June 4, 2024

due to the general lack of robust predictive biomarkers, a standardized risk stratification tool is not utilized in clinical practice – a prime area for research.”BUFFALO, NY- June 4, 2024 –... read more

Oncotarget

Behind the Study: Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167

May 30, 2024

Dr. Benoit Chabot from Université de Sherbrooke discusses a research paper he co-authored that was published by Oncotarget, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167... read more

Figure 1: Molecular structure of Silibinin.

Oncotarget

The Importance of Integrated Therapies on Cancer: Silibinin, an Old and New Molecule

May 28, 2024

This consideration could be the starting point to study whether Silibinin could contrast tumor progression, aging and inflammaging through molecular and cellular mechanisms [...].”BUFFALO, NY- May 28, 2024 – A new... read more

Table 8: Control data for transfection efficiency of uveal melanoma cells

Oncotarget

GZ17-6.02 Kills PDX Isolates of Uveal Melanoma

May 22, 2024

The present studies demonstrated that GZ17-6.02 interacted with irreversible inhibitors of the EGF receptor and HER2 to kill uveal melanoma cells.”BUFFALO, NY- May 22, 2024 – A new research... read more

Figure 4: Depletion of DHX33 antagonizes GPS167-mediated cytotoxicity.

Oncotarget

Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167 via EMT and Antiviral Immune Response

May 20, 2024

we have characterized a pair of compounds that impact multiple processes that are relevant to cancer cell proliferation but also, and possibly more importantly, to metastasis [...].”BUFFALO, NY- May 20,... read more